Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
: |4 Y7 |" N( Z5 W
) w+ i# \+ K- K( H4 |) v
8 ]) u( a+ L0 s& }* Q0 [Sub-category:
9 l( ]0 b5 [& b1 R' zMolecular Targets
2 _8 E' P. b4 \( l6 B H3 N; ?9 Y1 R+ K& k/ U" U$ l' T0 l. o6 y7 i
1 {' L- [$ i# Y: _% U1 R
Category:
; O5 e1 a3 g( V7 E; R; l% VTumor Biology
( h) b2 W7 Y5 W, {% Z. d
! N- r) _% D0 ~0 l0 S" l
b$ D8 _8 k8 ]% kMeeting:+ k1 z" I, B d4 _; {
2011 ASCO Annual Meeting ( P$ }" m* I6 d$ ^
/ M* U( S# V/ O: J+ r! L3 Y' |/ S8 n
Session Type and Session Title:# l n! j( |& \% m& z) v" S% g
Poster Discussion Session, Tumor Biology
1 v R5 n( z6 L+ |6 o: t& p( O5 P9 d7 i7 ~) P! v
" J% P, ]! x/ t _) C, P. s0 tAbstract No:
( }( Y4 b1 y) Z10517
/ c4 w' k+ s5 m2 @' Y0 k- Y# }5 K- Q! V
6 _$ R/ J; Q8 `% ^/ o$ x6 K# H J/ Y$ x" I+ d* T
Citation:
. z* q" L. {" R: eJ Clin Oncol 29: 2011 (suppl; abstr 10517)
1 a. o" U/ M3 w- s% j
8 U2 D. T0 y) F% w- z7 P+ o- n- `& }
( a- K5 ], P2 A" b/ W; P* wAuthor(s):
2 Z6 d% m( C2 U# G6 { {J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
& a4 M2 z$ V0 p1 g# U" g0 V3 Y2 L: P1 U
3 s h/ V: O% \- Z( k- h
2 t' e R; q+ h4 ^' B$ T9 V# Y% r. q
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.! U9 o5 W& r4 |9 K7 b! O& d2 g
" J* X2 v' M oAbstract Disclosures6 D1 Z9 W; b8 g0 A2 N
8 B: } x7 j( n, JAbstract:
4 a! ~! ?, h3 S# j) j9 ?4 P+ } E/ O% L# s6 K
- o E* y* c+ C: H
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.' B: e6 t% M, v4 m# r' l. s
; U6 c, j3 c, f3 L, f% S; O
' K% x# }: D" y0 G9 B" y" f6 E5 z |